Medpacto’s MP010 records 87.5% complete response rate in pancreatic cancer studies
AI Summary- Medpacto’s MP010 achieved complete responses against intractable pancreatic cancer in preclinical studies.
- 87.5% was the complete response rate recorded for MP010 in those studies.
- MP010 suppressed post-treatment recurrence and the development of heterogeneous cancers.